Novartis’s Rydapt wins EU approval for AML, other diseases

70

ZURICH (Reuters) – Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.
Source : http://in.reuters.com/